14 results on '"Gonzalez-Valcarcel, J"'
Search Results
2. Diagnóstico diferencial en la encefalitis por anticuerpos contra el receptor NMDA
- Author
-
González-Valcárcel, J., Rosenfeld, M.R., and Dalmau, J.
- Published
- 2010
- Full Text
- View/download PDF
3. Paracetamol, Ibuprofen, and Recurrent Major Cardiovascular and Major Bleeding Events in 19 120 Patients With Recent Ischemic Stroke
- Author
-
Gonzalez-Valcarcel, J, Sissani, L, Labreuche, J, Bousser, M-G, Chamorro, A, Fisher, M, Ford, I, Fox, KM, Hennerici, MG, Mattle, HP, Rothwell, PM, Steg, PG, Vicaut, E, Amarenco, P, and PERFORM Investigators
- Subjects
Male ,medicine.medical_specialty ,PERFORM Investigators ,Hemorrhage ,Ibuprofen ,030204 cardiovascular system & hematology ,1102 Cardiovascular Medicine And Haematology ,Brain Ischemia ,Brain ischemia ,cardiovascular events ,03 medical and health sciences ,0302 clinical medicine ,Interquartile range ,Recurrence ,Risk Factors ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,610 Medicine & health ,Stroke ,Acetaminophen ,Aged ,Advanced and Specialized Nursing ,Neurology & Neurosurgery ,business.industry ,organic chemicals ,1103 Clinical Sciences ,Analgesics, Non-Narcotic ,Middle Aged ,antiplatelet agent ,bleeding ,medicine.disease ,Terutroban ,Cardiovascular Diseases ,transient ischemic attack ,Anesthesia ,Female ,Neurology (clinical) ,1109 Neurosciences ,Cardiology and Cardiovascular Medicine ,business ,Major bleeding ,Mace ,medicine.drug - Abstract
Background and Purpose— The presumed safety of paracetamol in high–cardiovascular risk patients has been questioned. We determined whether paracetamol or ibuprofen use is associated with major cardiovascular events (MACE) or major bleeding in 19 120 patients with recent ischemic stroke or transient ischemic attack of mainly atherothrombotic origin included in the Prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) trial. Methods— We performed 2 nested case–control analysis (2153 cases with MACE during trial follow-up and 4306 controls matched on Essen stroke risk score; 809 cases with major bleeding matched with 1616 controls) and a separate time-varying analysis. Results— 12.3% were prescribed paracetamol and 2.5% ibuprofen. Median duration of treatment was 14 (interquartile range 5–145) days for paracetamol and 9 (5–30) days for ibuprofen. Paracetamol, but not ibuprofen, was associated with increased risk of MACE (odds ratio 1.21, 95% confidence interval [CI] 1.04–1.42) or a major bleeding (odds ratio 1.60, 95% CI 1.26–2.03), with no impact of daily dose and duration of paracetamol treatment. Time-varying analysis found an increased risk of MACE with both paracetamol (hazard ratio 1.22, 95% CI 1.05–1.43) and ibuprofen (hazard ratio 1.47, 95% CI 1.06–2.03) and of major bleeding with paracetamol (hazard ratio 1.95, 95% CI 1.45–2.62). Conclusions— There was a weak and inconsistent signal for association between paracetamol or ibuprofen and MACE or major bleeding, which may be related to either a genuine but modest effect of these drugs or to residual confounding. Clinical Trial Registration— http://www.isrctn.com . Unique identifier: ISRCTN66157730.
- Published
- 2015
4. Infarctus pontique paramédian révélant une neuroborréliose de Lyme : à propos d’un cas et revue de la littérature
- Author
-
Januel, E., primary, Deidier, J., additional, Gonzalez-Valcarcel, J., additional, Sirimarco, G., additional, Guidoux, C., additional, Caseris, M., additional, and Amarenco, P., additional
- Published
- 2014
- Full Text
- View/download PDF
5. Regresión de lesión quística de IV ventrículo tras tratamiento médico
- Author
-
González-Valcárcel, J., Fernández-Ruiz, L.C., Aparicio Hernández, M., Alonso Canovas, A., and Masjuan Vallejo, J.
- Published
- 2009
- Full Text
- View/download PDF
6. Neurology at the airport
- Author
-
Alonso-Canovas, A., primary, de Felipe-Mimbrera, A., additional, Gonzalez-Valcarcel, J., additional, Garcia-Barragan, N., additional, Corral, I., additional, and Masjuan, J., additional
- Published
- 2011
- Full Text
- View/download PDF
7. Outcomes after thrombolysis in AIS according to prior statin use: A registry and review.
- Author
-
Meseguer E, Mazighi M, Lapergue B, Labreuche J, Sirimarco G, Gonzalez-Valcarcel J, Lavallée PC, Cabrejo L, Guidoux C, Klein IF, Olivot JM, Rouchaud A, Desilles JP, and Amarenco P
- Published
- 2012
- Full Text
- View/download PDF
8. Paracetamol, Ibuprofen, and Recurrent Major Cardiovascular and Major Bleeding Events in 19 120 Patients With Recent Ischemic Stroke.
- Author
-
Gonzalez-Valcarcel J, Sissani L, Labreuche J, Bousser MG, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Mattle HP, Rothwell PM, Steg PG, Vicaut E, and Amarenco P
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Recurrence, Risk Factors, Acetaminophen adverse effects, Analgesics, Non-Narcotic adverse effects, Brain Ischemia complications, Cardiovascular Diseases etiology, Hemorrhage etiology, Ibuprofen adverse effects, Stroke complications
- Abstract
Background and Purpose: The presumed safety of paracetamol in high-cardiovascular risk patients has been questioned. We determined whether paracetamol or ibuprofen use is associated with major cardiovascular events (MACE) or major bleeding in 19 120 patients with recent ischemic stroke or transient ischemic attack of mainly atherothrombotic origin included in the Prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) trial., Methods: We performed 2 nested case-control analysis (2153 cases with MACE during trial follow-up and 4306 controls matched on Essen stroke risk score; 809 cases with major bleeding matched with 1616 controls) and a separate time-varying analysis., Results: 12.3% were prescribed paracetamol and 2.5% ibuprofen. Median duration of treatment was 14 (interquartile range 5-145) days for paracetamol and 9 (5-30) days for ibuprofen. Paracetamol, but not ibuprofen, was associated with increased risk of MACE (odds ratio 1.21, 95% confidence interval [CI] 1.04-1.42) or a major bleeding (odds ratio 1.60, 95% CI 1.26-2.03), with no impact of daily dose and duration of paracetamol treatment. Time-varying analysis found an increased risk of MACE with both paracetamol (hazard ratio 1.22, 95% CI 1.05-1.43) and ibuprofen (hazard ratio 1.47, 95% CI 1.06-2.03) and of major bleeding with paracetamol (hazard ratio 1.95, 95% CI 1.45-2.62)., Conclusions: There was a weak and inconsistent signal for association between paracetamol or ibuprofen and MACE or major bleeding, which may be related to either a genuine but modest effect of these drugs or to residual confounding., Clinical Trial Registration: http://www.isrctn.com. Unique identifier: ISRCTN66157730., (© 2016 American Heart Association, Inc.)
- Published
- 2016
- Full Text
- View/download PDF
9. Alteplase Reduces Downstream Microvascular Thrombosis and Improves the Benefit of Large Artery Recanalization in Stroke.
- Author
-
Desilles JP, Loyau S, Syvannarath V, Gonzalez-Valcarcel J, Cantier M, Louedec L, Lapergue B, Amarenco P, Ajzenberg N, Jandrot-Perrus M, Michel JB, Ho-Tin-Noe B, and Mazighi M
- Subjects
- Animals, Blood Platelets drug effects, Disease Models, Animal, Fibrin drug effects, Fibrin metabolism, Fibrinogen drug effects, Fibrinogen metabolism, Infarction, Middle Cerebral Artery pathology, Intracranial Thrombosis pathology, Leukocytes drug effects, Male, Microscopy, Fluorescence, Platelet Aggregation drug effects, Rats, Rats, Sprague-Dawley, Fibrinolytic Agents pharmacology, Infarction, Middle Cerebral Artery therapy, Intracranial Thrombosis prevention & control, Microvessels drug effects, Reperfusion, Tissue Plasminogen Activator pharmacology
- Abstract
Background and Purpose: Downstream microvascular thrombosis (DMT) is known to be a contributing factor to incomplete reperfusion in acute ischemic stroke. The aim of this study was to determine the timing of DMT with intravital imaging and to test the hypothesis that intravenous alteplase infusion could reduce DMT in a transient middle cerebral artery occlusion (MCAO) rat stroke model., Methods: Rats were subjected to 60-minute transient MCAO. Alteplase (10 mg/kg) was administered 30 minutes after the beginning of MCAO. Real-time intravital fluorescence microscopy through a dura-sparing craniotomy was used to visualize circulating blood cells and fibrinogen. Cerebral microvessel patency was quantitatively evaluated by fluorescein isothiocyanate-dextran perfusion., Results: Immediately after MCAO, platelet and leukocyte accumulation were observed mostly in the venous compartment. Within 30 minutes after MCAO, microthrombi and parietal fibrin deposits were detected in postcapillary microvessels. Alteplase treatment significantly (P=0.006) reduced infarct volume and increased the percentage of perfused vessels during MCAO (P=0.02) compared with saline. Plasma levels of fibrinogen from alteplase-treated rats showed a rapid and profound hypofibrinogenemia. In vitro platelet aggregation demonstrated that alteplase reduced platelet aggregation (P=0.0001) and facilitated platelet disaggregation (P=0.001). These effects were reversible in the presence of exogenous fibrinogen., Conclusions: Our data demonstrate that DMT is an early phenomenon initiated before recanalization. We further show that alteplase-dependent maintenance of downstream perfusion during MCAO improves acute ischemic stroke outcome through a fibrinogen-dependent platelet aggregation reduction. Our results indicate that early targeting of DMT represents a therapeutic strategy to improve the benefit of large artery recanalization in acute ischemic stroke., (© 2015 American Heart Association, Inc.)
- Published
- 2015
- Full Text
- View/download PDF
10. The smoking paradox: impact of smoking on recanalization in the setting of intra-arterial thrombolysis.
- Author
-
Meseguer E, Labreuche J, Gonzalez-Valcarcel J, Sirimarco G, Guidoux C, Cabrejo L, Lavallee PC, Klein IF, Amarenco P, and Mazighi M
- Abstract
Background: The smoking paradox refers to a better outcome in smokers eligible for thrombolytic treatment in myocardial infarction or ischemic stroke. Recent findings suggest that current smokers may present higher recanalization rates after intravenous (IV) thrombolysis with recombinant tissue plasminogen activator (rt-PA). We evaluated the impact of smoking in a consecutive series of patients treated with intra-arterial (IA) rt-PA., Methods: We analyzed data collected between April 2007 and December 2012 in our prospective registry. All acute ischemic stroke patients with an arterial occlusion treated by IA rt-PA (± IV, ± thrombectomy) were included. Arterial status was monitored with conventional angiography during the IA procedure. The primary study outcome was a complete recanalization achieved immediately after termination of IA rt-PA infusion. Secondary outcomes included complete recanalization after the end of the endovascular therapy (including complete recanalization achieved after adjunctive thrombectomy), favorable outcome (90-day modified Rankin Score ≤2), 90-day all-cause mortality, and any intracerebral hemorrhage., Results: Among the 227 included patients, 18.5% (n = 42) were current smokers and 16.7% (n = 38) former smokers. Compared with nonsmokers, current smokers were younger, more often men, had less frequently hypertension, and cardioembolic etiology, whereas former smokers were more often men and had more frequently hypercholesterolemia. The rate of complete recanalization was 30% (n = 68) after IA rt-PA infusion and 49% after adjunctive thrombectomy. A higher complete recanalization rate was found both in current smokers (45.2%) and former smokers (42.1%) compared to nonsmokers (22.5%). After adjustment for potential confounders, the adjusted odds ratio (OR) for complete recanalization associated with ever-smokers was 2.51 [95% confidence interval (CI) 1.26-4.99; p = 0.009]. A similar adjusted OR was found when the complete recanalization achieved after thrombectomy was included (OR 2.18, 95% CI 1.13-4.19; p = 0.019). However, smoking status was not independently associated with favorable outcome (adjusted OR 1.41, 95% CI 0.62-3.22 for former smokers, and adjusted OR 1.35, 95% CI 0.59-3.05 for current smokers), 90-day all-cause mortality (adjusted OR 0.68, 95% CI 0.25-1.81 for former smokers, and adjusted OR 1.55, 95% CI 0.54-4.48 for current smokers) or intracerebral hemorrhage (adjusted OR 0.72, 95% CI 0.29-1.76 for former smokers, and adjusted OR 0.80, 95% CI 0.32-1.96 for current smokers)., Conclusions: IA rt-PA administration was more effective to achieve complete arterial recanalization in current as well as former smokers. The characterization of the smoking paradox pathophysiology may lead to the identification of a patient-target population with a favorable response to rt-PA therapy. However, the smoking paradox should not be misinterpreted and not be used to promote smoking.
- Published
- 2014
- Full Text
- View/download PDF
11. Diabetes mellitus, admission glucose, and outcomes after stroke thrombolysis: a registry and systematic review.
- Author
-
Desilles JP, Meseguer E, Labreuche J, Lapergue B, Sirimarco G, Gonzalez-Valcarcel J, Lavallée P, Cabrejo L, Guidoux C, Klein I, Amarenco P, and Mazighi M
- Subjects
- Aged, Aged, 80 and over, Diabetes Mellitus blood, Female, Humans, Male, Middle Aged, Stroke blood, Stroke drug therapy, Blood Glucose analysis, Diabetes Mellitus epidemiology, Patient Admission, Registries, Stroke epidemiology, Thrombolytic Therapy methods, Treatment Outcome
- Abstract
Background and Purpose: The potential detrimental effect of diabetes mellitus and admission glucose level (AGL) on outcomes after stroke thrombolysis is unclear. We evaluated outcomes of patients treated by intravenous and/or intra-arterial therapy, according to diabetes mellitus and AGL., Methods: We analyzed data from a patient registry (n=704) and conducted a systematic review of previous observational studies. The primary study outcome was the percentage of patients who achieved a favorable outcome (modified Rankin score ≤2 at 3 months)., Results: We identified 54 previous reports that evaluated the effect of diabetes mellitus or AGL on outcomes after thrombolysis. In an unadjusted meta-analysis that included our registry data and previous available observational data, diabetes mellitus was associated with less favorable outcome (odds ratio [OR], 0.76; 95% confidence interval [CI], 0.73-0.79) and more symptomatic intracranial hemorrhage (OR, 1.38; 95% CI, 1.21-1.56). However, in multivariable analysis, diabetes mellitus remained associated with less favorable outcome (OR, 0.77; 95% CI, 0.69-0.87) but not with symptomatic intracranial hemorrhage (OR, 1.11; 95% CI, 0.83-1.48). In unadjusted and in adjusted meta-analysis, higher AGL was associated with less favorable outcome and more symptomatic intracranial hemorrhage; the adjusted OR (95% CI) per 1 mmol/L increase in AGL was 0.92 (0.90-0.94) for favorable outcome, and 1.09 (1.04-1.14) for symptomatic intracranial hemorrhage., Conclusions: These results confirm that AGL and history of diabetes mellitus are associated with poor clinical outcome after thrombolysis. AGL may be a surrogate marker of brain infarction severity rather than a causal factor. However, randomized controlled evidences are needed to address the significance of a tight glucose control during thrombolysis on clinical outcome.
- Published
- 2013
- Full Text
- View/download PDF
12. Is intracerebral hemorrhage a time-dependent phenomenon after successful combined intravenous and intra-arterial therapy?
- Author
-
Mosimann PJ, Sirimarco G, Meseguer E, Serfaty JM, Laissy JP, Labreuche J, Lapergue B, Gonzalez-Valcarcel J, Lavallée PC, Cabrejo L, Guidoux C, Klein IF, Olivot JM, Schouman-Claeys E, Amarenco P, and Mazighi M
- Subjects
- Fibrinolytic Agents administration & dosage, Fibrinolytic Agents therapeutic use, Humans, Injections, Intra-Articular, Injections, Intravenous, Prognosis, Prospective Studies, Registries, Retrospective Studies, Risk Factors, Stroke diagnosis, Time Factors, Cerebral Hemorrhage epidemiology, Stroke drug therapy, Thrombolytic Therapy, Tissue Plasminogen Activator administration & dosage, Tissue Plasminogen Activator therapeutic use
- Abstract
Background and Purpose: Onset-to-reperfusion time (ORT) has recently emerged as an essential prognostic factor in acute ischemic stroke therapy. Although favorable outcome is associated with reduced ORT, it remains unclear whether intracranial bleeding depends on ORT. We therefore sought to determine whether ORT influenced the risk and volume of intracerebral hemorrhage (ICH) after combined intravenous and intra-arterial therapy., Methods: Based on our prospective registry, we included 157 consecutive acute ischemic stroke patients successfully recanalized with combined intravenous and intra-arterial therapy between April 2007 and October 2011. Primary outcome was any ICH within 24 hours posttreatment. Secondary outcomes included occurrence of symptomatic ICH (sICH) and ICH volume measured with the ABC/2., Results: Any ICH occurred in 26% of the study sample (n=33). sICH occurred in 5.5% (n=7). Median ICH volume was 0.8 mL. ORT was increased in patients with ICH (median=260 minutes; interquartile range=230-306) compared with patients without ICH (median=226 minutes; interquartile range=200-281; P=0.008). In the setting of sICH, ORT reached a median of 300 minutes (interquartile range=276-401; P=0.004). The difference remained significant after adjustment for potential confounding factors (adjusted P=0.045 for ICH; adjusted P=0.002 for sICH). There was no correlation between ICH volume and ORT (r=0.16; P=0.33)., Conclusions: ORT influences the rate but not the volume of ICH and appears to be a critical predictor of symptomatic hemorrhage after successful combined intravenous and intra-arterial therapy. To minimize the risk of bleeding, revascularization should be achieved within 4.5 hours of stroke onset.
- Published
- 2013
- Full Text
- View/download PDF
13. Stroke mimics treated with thrombolysis: further evidence on safety and distinctive clinical features.
- Author
-
Guillan M, Alonso-Canovas A, Gonzalez-Valcarcel J, Garcia Barragan N, Garcia Caldentey J, Hernandez-Medrano I, Defelipe-Mimbrera A, Sanchez-Gonzalez V, Terecoasa E, Alonso de Leciñana M, and Masjuan J
- Subjects
- Acute Disease, Aged, Aged, 80 and over, Aphasia etiology, Brain Neoplasms diagnosis, Brain Neoplasms drug therapy, Cerebral Hemorrhage chemically induced, Cerebral Hemorrhage diagnosis, Diagnosis, Differential, Diagnostic Errors, Encephalitis diagnosis, Encephalitis drug therapy, Female, Fibrinolytic Agents administration & dosage, Fibrinolytic Agents adverse effects, Headache complications, Headache diagnosis, Hemianopsia etiology, Humans, Infusions, Intravenous, Male, Middle Aged, Neuroimaging, Paresis etiology, Recombinant Proteins administration & dosage, Recombinant Proteins adverse effects, Recombinant Proteins therapeutic use, Retrospective Studies, Somatoform Disorders diagnosis, Symptom Assessment, Treatment Outcome, Fibrinolytic Agents therapeutic use, Headache drug therapy, Somatoform Disorders drug therapy, Stroke diagnosis, Thrombolytic Therapy adverse effects, Tissue Plasminogen Activator therapeutic use
- Abstract
Background: Patients who present with symptoms mimicking ischaemic stroke (IS), but have a different diagnosis, are known as stroke mimics (SM). The necessity for rapid administration of intravenous thrombolysis in patients with acute IS may lead to treatment of patients with conditions mimicking stroke. A variable proportion of patients with SM (1.4-14%) are currently treated with intravenous tissue plasminogen activator therapy (IV-tPA). The outcome of these patients is generally favourable and complications are rather infrequent. We aimed to determine the frequency, clinical features and prognosis of SM patients treated with IV-tPA in an experienced stroke centre., Methods: A prospective registry was assembled with patients treated with IV-tPA at our stroke unit from January 2004 to December 2011. We recorded age, gender, baseline National Institutes of Health Stroke Scale (NIHSS) score, treatment delay, vascular risk factors, clinical syndrome and aetiology. We retrospectively analysed the clinical characteristics of SM, safety (symptomatic intracranial haemorrhage and mortality) and outcome measures (modified Rankin Scale at 3 months, mRS) and compared them with IS patients., Results: 621 patients were treated with IV-tPA during the study period, 606 (97.5%) were IS and 15 (2.4%) were SM. The aetiology of SM was somatoform disorders (5), headache and neurological deficits with cerebrospinal fluid lymphocytosis (HaNDL) syndrome (3), herpetic encephalitis (2), glial tumours (2), and migraine with aura, focal seizure and cortical vein thrombosis in single cases. SM were younger (72 ± 14 vs. 53.7 ± 16 years, p < 0.05), had a lower baseline deficit [NIHSS 13 (9-18) vs. 8 (5-10), p < 0.05], fewer vascular risk factors, and left hemisphere symptoms were predominant (80 vs. 52.4%, p < 0.05). Global aphasia without hemiparesis (GAWH) was the presenting symptom in 8 (54%) SM and 44 (7%) IS (p < 0.05). Multimodal computed tomography was performed in 3 SM patients and showed perfusion deficits in 2 of them. No intracranial haemorrhage or disability (functional outcome at 3 months, mRS >2) was recorded in any SM patient., Conclusions: The use of intravenous thrombolysis appears to be safe in our SM patients, and prognosis is universally favourable. Somatoform disorder and HaNDL syndrome were prominent causes, and GAWH the most common presentation. The safety of thrombolysis in SM suggests that delaying or withholding treatment may be inappropriate: the benefit of thrombolysis in case of IS may outweigh the risks of treating an SM. Further studies may assess the future role of multimodal computed tomography in the differential diagnosis between IS and SM., (Copyright © 2012 S. Karger AG, Basel.)
- Published
- 2012
- Full Text
- View/download PDF
14. Primary cerebral lymphomatoid granulomatosis as an immune reconstitution inflammatory syndrome in AIDS.
- Author
-
Gonzalez-Valcarcel J, Corral I, Quereda C, Alonso-Canovas A, Aparicio Hernandez M, de Felipe Mimbrera A, and García Villanueva M
- Subjects
- Acquired Immunodeficiency Syndrome drug therapy, Adult, Female, Humans, Immune Reconstitution Inflammatory Syndrome chemically induced, Leukoencephalopathies chemically induced, Lymphomatoid Granulomatosis chemically induced, Acquired Immunodeficiency Syndrome complications, Antiretroviral Therapy, Highly Active adverse effects, Immune Reconstitution Inflammatory Syndrome diagnosis, Leukoencephalopathies diagnosis, Lymphomatoid Granulomatosis diagnosis
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.